Peer-reviewed veterinary case report
Computational design of an improved photoswitchable psychedelic based on light absorption, membrane permeation and protein binding.
- Year:
- 2025
- Authors:
- Palmisano VF et al.
- Affiliation:
- Institute of Theoretical and Computational Chemistry · Germany
Abstract
Psychedelic compounds can induce rapid-acting and long-lasting antidepressant benefits. Understanding the role of their hallucinatory effects is crucial for shaping the future trajectory of antidepressant drug development. Photoswitchable compounds targeting the 5-HT<sub>2A</sub>R offer precise spatio-temporal control over the activation of different downstream pathways. In this work, we computationally discovered PQ-azo-<i>N</i>,<i>N</i>-DMT (34), a photoswitch with improved features compared to the previously synthesized azo-<i>N</i>,<i>N</i>-DMT (1). The new compound shows tight binding to the 5-HT<sub>2A</sub>R, retaining all important interactions of lysergic acid diethylamide (LSD), exhibits positive membrane permeability, and has a strong red-shifted absorption that would allow photocontrol in the visible spectrum.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://europepmc.org/article/MED/40879545